<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535222</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-CU-10-01</org_study_id>
    <nct_id>NCT01535222</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective CABG Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that periprocedural infusion of escalating doses
      of MDCO-2010 is safe and tolerated in patients undergoing elective CABG surgery, to
      characterize the single dose pharmacokinetics of MDCO-2010, to investigate the effect of
      MDCO-2010 on pharmacodynamics (biomarkers of fibrinolysis and coagulation parameters), and to
      investigate the effect on exploratory clinical endpoints of bleeding, transfusion
      requirements and reexploration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol describes a study of the investigational drug MDCO-2010 as a haemostasis
      modulator in patients undergoing elective Coronary Artery Bypass Graft (CABG) surgery
      involving a cardiopulmonary bypass (CPB).

      Perioperative bleeding is a serious complication that adversely affects the morbidity and
      mortality of cardiac surgery. To alleviate this complication, prophylactic antifibrinolytic
      therapies are now widely accepted as a strategy to inhibit excessive fibrinolysis.

      MDCO-2010, a synthetic small molecule, is a direct inhibitor of plasmin and plasma
      kallikrein. Both of these have been implicated with impaired haemostasis. In addition, potent
      inhibition of coagulation factors Xa, XIa and activated Protein C has been demonstrated.
      Thus, MDCO-2010 has the potential to mitigate excessive fibrinolysis and thrombin generation
      during cardiac surgery involving a cardiopulmonary bypass. In particular the latter is
      supposed to provide additional benefits beyond reducing transfusion requirements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>7 days (day of surgery to day 7)</time_frame>
    <description>Number of patients experiencing Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>7 days (day of surgery to day 7)</time_frame>
    <description>Number of patients experiencing Serious Adverse Events</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Coronary Artery Bypass Graft</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDCO-2010</intervention_name>
    <description>MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>CU-2010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Commercially available NaCl</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Men, aged 18 to 80 years or

          -  Post-menopausal women, aged up to 80 years. Postmenopausal status defined as ≥ 1 year
             since last menstruation in women with no medical history of hysterectomy or women with
             a medical history of bilateral oophorectomy

          -  Planned elective, isolated primary CABG surgery with more than 1 graft, including the
             use of cardiopulmonary bypass

          -  Written informed consent prior to any study-related procedure not part of normal
             medical care

        Exclusion Criteria

        Patients may not meet any of the following exclusion criteria:

          -  Planned concomitant surgery including atrial septal defect (ASD) repair, valve
             replacement, carotid endarterectomy, aortic surgery, any combined procedure or any
             repeat sternotomy

          -  Planned Off-pump CABG

          -  Body weight &lt; 55 kg or &gt; 110 kg

          -  Planned hypothermia &lt; 28°C

          -  Major surgical procedures within 30 days of entry

          -  Placement of drug-eluting stent (DES) within 12 months or of bare-metal stent (BMS)
             within 6 weeks of entry in a vessel which is not intended to be grafted

          -  Ejection fraction &lt; 35%

          -  Preoperative coagulation abnormalities

               -  Platelet count &lt; 100,000/cubic mm, or

               -  INR &gt; 1.5 or Quick &lt; 40%, or

               -  activated partial thromboplastin time (aPTT) &gt; 1.5 x upper limit of normal (ULN)

          -  Preoperative Hb &lt; 11 g/dL for male patients or &lt; 10 g/dL for female patients

          -  Patient refusal to receive donor blood products if necessary

          -  Administration of thienopyridines within 5 days prior to surgery Administration of
             warfarin within 5 days prior to surgery

          -  Administration of tirofiban or eptifibatide within 24 hours or administration of
             abciximab within 5 days prior to surgery

          -  Administration of fondaparinux within 24 hours prior to surgery

          -  Creatinine clearance (calculated using Cockroft-Gault equation) &lt; 60 mL/min

          -  Planned intraoperative use of tranexamic acid or of ε-aminocaproic acid

          -  History of stroke or transient ischemic attack within 3 months prior to entry

          -  Known heparin-induced thrombocytopenia

          -  Known history of thrombophilia, eg, deep vein thrombosis (DVT) with pulmonary embolism

          -  Active liver disease

          -  Any condition requiring chronic immunosuppressive medication

          -  Receipt of an investigational drug or device 30 days prior to entry

          -  Any other condition which, in the opinion of the investigator, would prevent a
             patient's participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Englberger, PD Dr. Med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Bern</affiliation>
  </overall_official>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <results_first_submitted>June 14, 2012</results_first_submitted>
  <results_first_submitted_qc>June 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2012</results_first_posted>
  <last_update_submitted>June 14, 2012</last_update_submitted>
  <last_update_submitted_qc>June 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac surgery</keyword>
  <keyword>coronary artery bypass graft</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <keyword>haemostasis modulator</keyword>
  <keyword>blood loss</keyword>
  <keyword>direct inhibitor of plasmin and plasma kallikrein</keyword>
  <keyword>CABG</keyword>
  <keyword>CPB</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4</title>
          <description>loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5</title>
          <description>loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7">Patient randomized but did not meet inclusion/exclusion criteria and did not receive study drug</participants>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inclusion/exclusion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4</title>
          <description>loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5</title>
          <description>loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="12.1"/>
                    <measurement group_id="B2" value="62" spread="10.8"/>
                    <measurement group_id="B3" value="59" spread="8.3"/>
                    <measurement group_id="B4" value="68" spread="9.6"/>
                    <measurement group_id="B5" value="63.2" spread="12.4"/>
                    <measurement group_id="B6" value="65.9" spread="5.6"/>
                    <measurement group_id="B7" value="63.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events</title>
        <description>Number of patients experiencing Adverse Events</description>
        <time_frame>7 days (day of surgery to day 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Number of patients experiencing Adverse Events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>Number of patients experiencing Serious Adverse Events</description>
        <time_frame>7 days (day of surgery to day 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>Number of patients experiencing Serious Adverse Events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4</title>
          <description>loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5</title>
          <description>loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural MI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase (ALAT) increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase (ASAT) increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase MB increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor can review results communications prior to public release. Sponsor will complete review within 60 days. If Sponsor believes proposed publication contains patentable information, disclosure shall be delayed to 90 days to permit patent filing. If additional time is required an extension shall be granted not to exceed an additional 90 days. If Sponsor believes proposed publication contains confidential information, site shall delete such information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andreas van de Locht</name_or_title>
      <organization>The Medicines Company</organization>
      <phone>+4989244180862</phone>
      <email>andreas.locht@themedco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

